Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etoricoxib/tizanidine - Merck Sharp & Dohme

Next Previous
X
Search
Drug Profile

Etoricoxib/tizanidine - Merck Sharp & Dohme

Alternative Names: Etoricoxib/tizanidine MR; Immediate-release etoricoxib/modified-release tizanidine - Merck; MK-0663B; Tizanidine/etoricoxib

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antirheumatics; Antispastics; Imidazolines; Muscle relaxants; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Musculoskeletal pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-pain in USA (PO, Tablet)
  • 01 Apr 2015 Merck terminates a phase III trial for Back pain in USA prior to enrolment (NCT01979510)
  • 08 Nov 2013 Merck plans a phase III trial for Back pain in USA (NCT01979510)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top